Seres Therapeutics, Inc.
Symbol: MCRB (NASDAQ)
Company Description:
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
- Today's Open: $17.83
- Today's High: $18.61
- Today's Low: $17.195
- Today's Volume: 202.50K
- Yesterday Close: $17.59
- Yesterday High: $19.9071
- Yesterday Low: $17
- Yesterday Volume: 431.23K
- Last Min Volume: 120
- Last Min High: $17.844
- Last Min Low: $17.816
- Last Min VWAP: $17.816
- Name: Seres Therapeutics, Inc.
- Website: https://www.serestherapeutics.com
- Listed Date: 2015-06-26
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001609809
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $153.99M
- Round Lot: 100
- Outstanding Shares: 8.75M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-19 | 4 | View |
| 2025-08-19 | 4 | View |
| 2025-08-19 | 4 | View |
| 2025-08-19 | 4 | View |
| 2025-08-06 | 4 | View |
| 2025-08-06 | 3 | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-22 | 8-K | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-06-06 | SCHEDULE 13G/A | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-07 | S-8 | View |
| 2025-05-07 | 10-Q | View |